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Abstract A great effort has been exerted to develop drug
carriers aiming at satisfying the requirements, such as
safety, greater efficiency, predictable therapeutic response,
and prolonged release period. The present study aims at
developing the use of zinc oxide nanoparticles as a carrier
as a function of particle size for amoxicillin drug delivery
system. The amoxicillin-loaded zinc oxide nanoparticles
have a good antibacterial activity against infectious Gram-
positive and Gram-negative bacteria. Zinc oxide nanopar-
ticles have been prepared by wet chemical precipitation
method varying the pH values. Particle size and morphol-
ogy of the as-prepared ZnO powders are characterized by
X-ray diffraction, Fourier transform infrared spectroscopy
and transmission electron microscope. Drug loading, in
vitro drug release and antibacterial activity have been
analyzed. Maximum zone of inhibition is observed for
Staphylococcus epidermis. The results show that inhibitory
efficacy of drug-loaded ZnO nanoparticles is very much
dependent on its chosen concentration, drug loading, and
size.
Keywords Amoxicillin  ZnO nanoparticles 
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Introduction
Over the past few years, local delivery systems have
attracted much attention due to their efficacy to improve
the ingrowth and regeneration of bones and teeth (Kim
et al. 2004). Drugs, such as antibiotics, anti-tumors, and
growth factors, have been administered to the defect
regions to induce therapeutic effects (Di Silvio and Bon-
field 1999). A great deal of effort has been exerted to
develop drug carriers, in the form of foams, films, and
microspheres, aiming at satisfying the requirements, such
as safety, greater efficiency, predictable therapeutic
response and prolonged release period (Gautier et al.
2001). Due to the large surface-to-volume ratio the nano-
particles are very useful for attaching drug molecules and
other compounds (De Jong and Borm 2008). Nanoscale
devices, smaller than 50 nm, can easily enter most cells
and circulate through the body through blood vessels
(Courrier et al. 2002). The advances in micro and nano-
fabrication technology have enhanced the tools available to
create clinically important therapeutic applications (Lu and
Chen 2004).
Controlled drug delivery is the technology by which the
drugs can be released at a predetermined rate for a long
period of time in the blood stream or delivered at the target
site (Kamaly et al. 2012). Unlike the traditional oral,
intravenous drug delivery methods whereby the drug is
distributed to both healthy and diseased tissue, in con-
trolled local drug delivery high concentration of drug is
achieved at the infected site. This leads to increase in
therapeutic index and therapeutic efficacy and abridged
side effects to other organs (Melville et al. 2008; Noel et al.
2008). Drug stability, optimized drug absorption, treatment
continuation in natural phase improvement in pharmaco-
kinetic characteristics of drug can be achieved by localized
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drug delivery (Smola et al. 2008). In controlled drug
delivery system, the carrier plays a vital role since they
incorporate the drug, retain it, and release it progressively
with time. So, properties such as (1) drug incorporation and
release, (2) formulation stability and shelf life, (3) bio-
compatibility, (4) bio-distribution, and (5) functionality
must be analyzed thoroughly when choosing a carrier for
delivery of drugs. The drug release from any carrier
depends upon solubility of drugs, microstructure of carrier,
degradation of carrier, and the bond between the drug and
carrier (De Jong and Borm 2008). The application of
nanotechnology to medical applications, commonly refer-
red to as ‘‘nanomedicine’’, seeks to deliver a new set of
tools, devices and therapies for treatment of human disease
(Rasmussen et al. 2010). The potential use of zinc oxide
(ZnO) and other metal oxide nanoparticles in biomedical
and cancer applications is gaining attention in the scientific
and medical communities, largely due to the physical and
chemical properties of these nanomaterials (Rasmussen
et al. 2010). ZnO is one of the five zinc compounds which
are currently recognized as safe for nutrients by the US
Food and Drug Administration (21CFR182.8991). ZnO
nanoparticles (NPs) are widely used in many consumer
products like cosmetics, toothpaste, textiles, and skin
lotions (Ng et al. 2010).
Amoxicillin trihydrate is a semi synthetic antibiotic with
a broad spectrum of bactericidal activity against many
Gram-positive and Gram-negative, aerobic and anaerobic
microorganisms. It does not resist destruction by b-lacta-
mases; therefore, it is not effective against b-lactamase-
producing bacteria. Chemically, it is d(-)-a-amino-p-//
hydroxybenzyl penicillin trihydrate. Amoxicillin is an
excellent agent to treat otitis media, bacterial sinusitis, and
bacterial exacerbations of bronchitis, acute lower-urinary-
tract infections, gonorrhea, and typhoid (Khuroo et al.
2008). Staphylococcus aureus and Staphylococcus epide-
rmidis are natural inhabitants of human and animal skin,
but it can sometimes cause infections that affect many
organs (Bhunia 2008). S. aureus is one among the most
important pathogens that cause bone and joint infections,
soft tissue and overwhelming sepsis and express many
surface adhesions that promote attachment to plasma and
extra cellular matrix (ECM) proteins of the host cell
(Venkatasubbu et al. 2011). The pathogenic bacteria
Klebsiella pneumonia and Enterobacter aerogenes are the
major causative agents of noso-comial infections (Saonu-
am et al. 2008). Serotype paratyphi B var. L (?) tartrate
(?) causes a typical Salmonella gastroenteritis instead of
enteric fever (Prager et al. 2003).
In the present work different sizes of zinc oxide were
synthesized in nano form and characterized. Amoxicillin
was loaded to these ZnO nanoparticles. The various
parameters for drug loading were optimized. The drug
loading percentage, stirring time and the influence of drug
release profile on these parameters were analyzed. The
interaction between nanoparticles and drug was analyzed.
Antibacterial response of drug-loaded nanoparticles against
infectious Gram-positive and Gram-negative microbes was
investigated.
Materials and methods
Synthesis and characterization of ZnO nanoparticles
Zinc oxide nanoparticles were synthesized with a slight
modification suggested by Wu et al. (2006) from aqueous
solutions of zinc nitrate (Zn (NO3)26H2O) (purchased
from Fischer Chemicals, Mumbai, India; Purity 96 %) and
hexamethyltetramine (HMT) (C6H12N4) (purchased from
Qualigens Chemicals, Mumbai, India; Purity 99 %). The
two chemicals were mixed separately with milli-Q water to
a concentration of 0.05 M for the (Zn (NO3)2) solution and
1.5 M for the HMT solution. The separate solutions were
stirred for 30 min each and then mixed with 130 rpm
stirring. The solutions were adjusted to the desired pH (5.0,
6.0 and 7.2) and heated to 80 C for 45 min. The product
was collected by centrifugation (Compufuge, Model CPR
32, Remi Electrotechnik Limited, Thane, India). The
ammonium hydroxide solution (one normality solution)
was added to pH 5.0 synthesized solutions to enhance the
formation of ZnO at 80 C (Wu et al. 2006).
Particle characterization
Powder X-ray Diffraction (XRD, Seifert, JSO-DE BYE-
FLEX 2002, Germany) was used to identify the crystalline
phase composition and purity. The phase was found to be
hexagonal and no impurity peaks were found. The mor-
phology and grain size of the ZnO were observed by
TECNAI G2 Model T-30 S-twin high-resolution transmis-
sion electron microscopy (HRTEM). The quality of the
ZnO NPs was analyzed by FTIR (FTIR, Perkin Elmer
Spectrum One). The size distributions were performed in a
dilute aqueous nanoparticle suspension at pH 7.0 with
particle size analyzer (Malvern S particle size analyzer).
Drug loading
In order to load the drug into ZnO nanoparticles, amoxi-
cillin trihydrate was dissolved in 100 ml of distilled water
at different concentrations (1, 3, 5 and 10 %). 1 g of dif-
ferent sizes of ZnO nanoparticles was added to all the three
drug solutions and stirred using magnetic stirrer at 600 rpm
for various time periods (30, 60 and 120 min) at room
temperature. Then the solution was left undisturbed
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overnight. The suspension was then centrifuged at
5,000 rpm for 5 min and the supernatant and precipitate
were separated. The amount of loaded drug was determined
by finding the difference in amoxicillin concentration in the
aqueous solution before and after drug loading. Percentage
of drug loading was calculated using the following
equation:
Percentage of drug loading ¼ ðA  BÞ=A½   100
where A and B represent the initial and final drug con-
centration of the aqueous drug solution (Hamblett et al.
2004; Venkatasubbu et al. 2011). The attachment of
amoxicillin with ZnO nanoparticles was analyzed by FTIR
(FTIR, Perkin Elmer Spectrum One).
In vitro drug release studies
In order to determine the drug release profile, 100 mg of
the drug loaded ZnO nanoparticles was introduced into a
screw-capped (100 ml) glass bottle containing 50 ml of
phosphate-buffered saline (PBS) medium at 37 C and pH
7.4 under sterile condition. In vitro drug release study was
done for a period of 650 h. 5 ml samples were withdrawn
by a pipette and centrifuged at 5,000 rpm and replaced
immediately with 5 ml of fresh PBS medium, which was
accounted for when calculating the amount released.
Amoxicillin concentration in the supernatant was measured
spectrophotometrically at a wavelength of 230 nm. The pH
in the media at different intervals was estimated. The
experiments were repeated thrice.
Antimicrobial assay
The antibacterial assay of drug-loaded ZnO nanoparticles
with different sizes was tested by disc-diffusion method
(Jayaseelan et al. 2012). The following bacteria were used
for the experiments: Salmonella paratyphi-B, Klebsiella
pneumoniae MTCC 109, Bacillus subtilis MTCC 441,
Enterobacter aerogenes MTCC 111 and Staphylococcus
epidermidis MTCC 3615. The reference cultures were
obtained from Institute of Microbial Technology (IMTECH),
Chandigarh, India-160 036. Petri plates were prepared with
20 ml of sterile Mueller–Hinton agar (MHA) (Himedia,
Mumbai). The test cultures were swabbed on the top of the
solidified media and allowed to dry at room temperature for
10 min. The suspension of drug loaded nanoparticles (in
milli-Q water) was used to prepare 50, 100 and
200 lg ml-1 added to each well separately (8 mm diam-
eter). Amoxicillin trihydrate (25 lg/disc; purchased from
Himedia Chemicals Ltd., Mumbai, India) was used as
positive control. The plates were incubated for 24 h at
37 C. Zones of inhibition were recorded in millimeters by
repeating the experiment thrice for each concentration.
Statistical analysis
Experiments were repeated thrice and results were pre-
sented as means and standard deviations from the three
replicates. Drug release, pH buffer data, and antimicrobial
assay were evaluated by one-way analysis of variance
(ANOVA) in combination with Tukey’s multiple compar-
ison tests. A significance level of P \ 0.05 was considered
statistically significant.
Results and discussion
The present study employed a low-temperature synthesis
method to prepare ZnO NPs. Zinc nitrate and HMT solu-
tions were mixed at 80 C for 45 min at different pH. After
precipitation of ZnO, the pH value was found to be 8.2.
The XRD pattern of synthesized ZnO nanoparticles dem-
onstrated that the nano ZnO to be crystalline in nature, and
the diffraction peaks matched very well with hexagonal
zincite phase of ZnO (Fig. 1). The diffraction pattern and
inter-planar spacing closely matched those in the standard
diffraction pattern of ZnO (powder diffraction file ICDD
36-1451: a = 3.249 A˚ and c = 5.206 A˚). The XRD peaks
show (100), (002), (101), (102), (110), (103), (200), and
(201) reflection lines of hexagonal zincite phase of ZnO
particles. No characteristic peaks of any impurities were
found suggesting good-quality ZnO nano powders. The
particle size based on broadening has been analyzed by
Scherrer formula, modified forms of Williamson-Hall
analysis, and size-strain plot method. The crystalline size
can be calculated using the following equation:
ðdhklbhkl cos hÞ2 ¼ K=D ðd2hklbhkl cos hÞ þ ðe=2Þ2
where K is the constant that depends on the shape of the
particles. The particle size has been determined from the
slope of linearly fitted data. The root of the y intercept
gives the strain (Zak et al. 2011).
The functional or composition quality of the synthesized
product has been analyzed by the FTIR spectroscopy.
Figure 2 shows the FTIR spectrum acquired in the range of
400–4,000 cm-1. The band at 535 cm-1 corresponds to the
stretching vibration of Zn–O bond. The broad absorption
bands in the range 3,900–2,350 cm-1 and 1,637 cm-1
correspond to the presence of the surface hydroxyl groups
(Sharma et al. 2009). C–OH stretching (1,387 cm-1) is
detected from the FT-IR spectrum (Song et al. 2008). The
band at 1,387 cm-1 corresponds to the CH2 deformation,
and absorption bands at 1,235–1,125 cm-1 are responsible
for CN stretch. 998 cm-1 and 897 cm-1 correspond to CH2
rock (Bernstein et al. 1994). The TEM image of pure ZnO
nanoparticles is presented in Fig. 3. The insert Fig. 3 is
particle size distribution as measured by dynamic light
Appl Nanosci (2013) 3:441–451 443
123
scattering (DLS). The TEM images confirm the formation
of hexagonal structure of ZnO and are in agreement with
the XRD results. The particle size of the ZnO prepared
at different pH are 38 ± 2, 25 ± 4 and 15 ± 4 nm in
as-prepared, pH 6.0 and 5.0 respectively.
The structure of the amoxicillin-loaded ZnO nanoparti-
cles analyzed using FTIR spectroscopy is shown in Fig. 4.
Characteristics bands of both ZnO and amoxicillin are
observed for all ZnO/drug samples. The ZnO nanoparticles
loaded with drug represent mixed bands typical of ZnO
nanoparticles, where 3,900–2,375 cm-1 corresponds to the
presence of the surface hydroxyl groups and amoxicillin
major peaks observed at 3,359 cm-1 (amide NH and
phenol OH stretch), 2,971 and 2,375 cm-1 benzene ring
CH stretch, 1,583 cm-1 benzene ring C=C stretch,
1,398 cm-1 (NH bend CB stretch combination band and
NH3? symmetric deformation (Kumar et al. 2011). The
peaks observed between 1,573 and 739 cm-1 in amoxi-
cillin-loaded ZnO nanoparticles comply with peak of ZnO
and amoxicillin trihydrate and indicate that the amoxicillin
is compatible with ZnO.
Drug loading
The drug loading efficiency of ZnO nanoparticles has been
examined as described previously. It is dependent on the
concentration of drug, size of nanoparticles and the ratio of
drug and ZnO NPs. The drug loading percentage increases
with increase in these parameters. It increases and becomes
constant at a particular level. The variation in drug loading
with change in drug concentration is shown in Table 1. For
1 and 3 % drug concentration, the drug loading is 60 and
80 % and it increases to 90 % at 5 and 10 % drug con-
centration and remains to be 90 % for both these concen-
trations for 15 nm size ZnO. The drug loading is 87 % for
5 and 10 % drug concentration in 25 and 38 nm ZnO NPs.
The variation in drug loading with change in stirring time is
given in Table 2. With 1 and 3 % drug concentration and
stirring at 30 min, the drug loading is found to be 37 and
49 % and it increases to 62 and 79 % at 5 % and 10 %
drug concentration for 15 nm ZnO NPs. Maximum drug
Fig. 1 XRD Pattern of ZnO
prepared at different pH. a As-
prepared, b pH 6.0, c pH 5.0
Fig. 2 FTIR spectrum of as-prepared ZnO nanoparticles. a As-
prepared, b pH 6.0, c pH 5.0
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loading is obtained at 60 and 120 min and then it becomes
constant for all the three different sizes of nanoparticles.
In vitro drug release
Many carrier systems are used for the controlled delivery
of amoxicillin. Polyethyleneglycol-coated polycyanoacry-
late nanoparticles loaded with amoxicillin have been used
for phagocytic uptake (Fontana et al. 2001). The study
reports the release profile of amoxicillin at different pH 7.4,
4.0 and 1.1 in comparison with urease. This work reports
the release studies at pH 7.4 and in human plasma evi-
dences that the amoxicillin release occurs with a biphasic
profile with an initially rapid followed by zero-order
kinetics. Nanoparticles incorporated in pH-sensitive
hydrogels as amoxicillin delivery for eradication of Heli-
cobacter pyroli (Chang et al. 2010). The results of drug
releasing in vitro study clearly indicate that the amount of
amoxicillin released from nanoparticles incorporated in
hydrogels in pH 1.2 is relatively low (14 %), compared
with that from only nanoparticles (50 %). The sustained
release of amoxicillin from chitosan tablets was investi-
gated by Sahasathian et al. (2007). These authors have
shown that chitosan with the particle size less than 75 lm
is able to provide a significantly improved sustained release
profile of amoxicillin compared with release profile of a
commercial capsule. Amoxicillin release kinetics of
gamma-irradiated chitosan/pHEMA membranes have
shown that the amount of drug release is dependent on
membrane network crosslinking due composition, radiation
and membrane thickness (Casimiro et al. 2007).
In this work, amoxicillin has been loaded on ZnO to
investigate the efficacy of the drug delivery system. The
different drug release profiles are illustrated in Fig. 5. The
estimated percentages of drug released in 648 h are found
to be 60, 80, and 90 % from 1, 3, 5, and 10 % drug-loaded
Fig. 3 TEM images of ZnO nanoparticles prepared at different pH (inset picture describes particle distribution and size in aqueous suspension).
a As prepared, b pH 6.0, c pH 5.0
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samples, respectively. The drug release increases gradually
over a period of time. This shows that the drug is released
in a controlled manner. The amount of drug released in
24 h of time is well above the minimum inhibition con-
centration of amoxicillin which is up to 25 lg ml-1 for
infectious pathogens. Such an observed release profile will
provide a rapid delivery of drug to give antibacterial effects
at the infected site and a sustained release to aid long-term
Fig. 4 FTIR Spectrum of drug loaded nanoparticles. a FTIR
spectrum of amoxicillin, b FTIR spectrum of drug loaded 15 nm
ZnO NPs at a 1:3 ratio and b 1:5 ratio






















Table 2 Drug loading percentage with different stirring time
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healing and avoid the toxic and adverse systemic effects
caused by high concentration of antibiotics. The release of
drug from ZnO NPs exhibits a two stage release mecha-
nisms. The drug release is high during the initial time and
then it reduces and becomes stable. Amoxicillin release
during the initial burst stage is due to adsorption of drug
molecules that are located on the surface of the particles
(Fontana et al. 2001). These particles do not strongly
interact with the ZnO NPs. During the in vitro drug release
analysis, the ZnO absorbs the surrounding fluids into the
nanoparticles. This leads to the dissolution and exclusion of
the loaded amoxicillin. The smaller the particles, the more
Fig. 5 Drug release profile in
a Amoxicillin loaded on
15 nm ZnO nanoparticles,
b Amoxicillin loaded on
25 nm ZnO nanoparticles,
c Amoxicillin loaded on 38 nm
ZnO nanoparticles
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Fig. 6 Antimicrobial activity
of amoxicillin-loaded ZnO
nanoparticles in a gram-positive
bacteria, b Gram-negative
bacteria. *P \ 0.05 statistically
significant when compared with
control
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the exposure of amoxicillin to the fluid. When the loosely
adsorbed drug has almost completely desorbed, the drug
release becomes slow. The slow release of amoxicillin is
due to the incorporation of the drug ZnO NPs.
Antibacterial activity
The re-emergence of infectious diseases poses a serious
threat to public health. The increasing rate of the appear-
ance of antibiotic-resistant strains in a short period of time
within both Gram-positive and Gram-negative microor-
ganisms is a major public health concern (Jones et al. 2008).
Alternative therapeutics to control and prevent the spread of
infections in both community and hospital environments are
required (Sharma et al. 2009). The results of antibacterial
activity of different sizes of drug-loaded ZnO NPs are
shown in Fig. 6a and b. The zone of inhibition (in mm)
reflects magnitude of susceptibility of the microorganism.
The strains susceptible to nanoparticles exhibit larger zone
of inhibition, whereas resistant strains exhibit smaller one.
Significant difference between each concentration has been
compared. Maximum zone of inhibition has been observed
for S. epidermis. Increase in drug loading concentration
significantly (P \ 0.05) increases the zone of inhibition
from 1 to 3 % drug concentration. Insignificant differences
between zones of inhibition are observed for 5 and 10 %
drug concentration. Highest zones of inhibition are
observed for drug-loaded 15 nm ZnO NPs.
The antibacterial activity of ZnO NPs from the present
results suggests that ZnO nanoparticles may play differ-
ential response to various tested microorganisms. This may
be consistent with the prediction that S. epidermis can
Fig. 6 continued
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metabolize Zn2? as an oligo element (Roselli et al. 2003).
Similarly, metal-ion homeostasis is important for bacterial
life because of their involvement in the regulation of a
wide array of metabolic functions asco-enzymes, cofactors,
and catalysts, and as structural stabilizers of enzymes and
DNA-binding proteins (Padmavathy and Vijayaraghavan
2003). However, excess metal or metal ions are toxic for
bacterial cells. Therefore, certain bacteria have developed
mechanisms to regulate the influx and efflux processes to
maintain the steady intracellular concentration of metal
ions, including the Zn2? ion (Gaballa et al. 2002). The
higher antibacterial activity of drug loaded ZnO nanopar-
ticles in S. epidermis may involve the production of reac-
tive oxygen species (ROS) and the deposition on the
surface or accumulation in the cytoplasm of the cells as
observed in earlier studies for S. aureus (Raghupathi et al.
2011). The results obtained in our study indicate that the
inhibitory efficacy of drug-loaded ZnO nanoparticles is
very much dependent on its chosen concentration, drug
loading, and size which are similar to other related findings
(Yin et al. 2010; Wahab et al. 2010).
Amoxicillin trihydrate is currently marketed as tablets
(floating tablets) of 250 and 500 mg. The long-term
administration of amoxicillin trihydrate is required against
Streptococcal pharyngitis (http://www.healthystock.net/drugs/
amoxicillin.shtml).
The presently available conventional therapy is associ-
ated with a number of drawbacks such as highly variable
absorption and low bioavailability after oral administration
(Bhosale et al. 2011). Furthermore, with increase in dose,
there is decrease in bioavailability. Maximal therapeutic
efficacy needs to be coupled with minimal toxicity, a goal
which can be achieved by formulating drugs with nano-
particles (Horwitz et al. 2010).
Conclusion
A drug delivery system with different sizes of ZnO NPs has
been developed to treat against infectious bacteria. ZnO
NPs can be used as drug delivery system for the controlled
delivery of amoxicillin. The antimicrobial property
increases with increase in the drug loading and becomes
stable at 5 and 10 % drug loading. The drug loading
depends on the size of nanoparticles, concentrations of
drug, and stirring time. The drug loading increases with
increase in stirring time and drug concentration. The drug
release profile from all three sizes of ZnO NPs shows a
controlled release. The antibacterial investigations of
amoxicillin loaded on nano ZnO with particle sizes of 15,
25, and 38 nm have been carried out. The bacteria inves-
tigated in this work are Gram positive and Gram negative
and it is found that the antibacterial activity of amoxicillin
loaded on nano ZnO is insignificant for E. aerogenes and
K. pneumoniae.
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